Mednax Company Insiders

MD Stock  USD 10.03  0.04  0.40%   
Mednax's insiders are aggressively selling. The analysis of insiders' sentiment of trading Mednax Inc stock suggests that all insiders are panicking at this time. Mednax employs about 5.5 K people. The company is managed by 43 executives with a total tenure of roughly 298 years, averaging almost 6.0 years of service per executive, having 126.74 employees per reported executive.
Roger Medel  CEO
Chief Executive Officer, Director
Cesar Alvarez  Chairman
Independent Chairman of the Board

Mednax's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2023-12-14Mary Ann E MooreDisposed 970 @ 9.62View
2023-06-14James D SwiftDisposed 13193 @ 14.14View
2023-05-25Mark S OrdanDisposed 33000 @ 13.26View
2023-05-18Shirley A WeisDisposed 17993 @ 13.55View
Monitoring Mednax's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Mednax's latest congressional trading

Congressional trading in companies like Mednax Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Mednax by those in governmental positions are based on the same information available to the general public.
2019-10-15Representative Donna ShalalaDisposed $50K to $100KVerify
2018-10-26Representative Greg GianforteDisposed $50K to $100KVerify

Mednax Management Team Effectiveness

The company has Return on Asset (ROA) of 0.0432 % which means that for every $100 of assets, it generated a profit of $0.0432. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.0694) %, which implies that it produced no returns to current stockholders. Mednax's management efficiency ratios could be used to measure how well Mednax manages its routine affairs as well as how well it operates its assets and liabilities. As of March 29, 2024, Return On Capital Employed is expected to decline to 0. The current year's Return On Assets is expected to grow to -0.03. At present, Mednax's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 86.3 M, whereas Total Current Assets are forecasted to decline to about 382.4 M.
As of March 29, 2024, Common Stock Shares Outstanding is expected to decline to about 77.1 M. In addition to that, Net Income Applicable To Common Shares is expected to decline to about 48.1 M

Mednax Workforce Comparison

Mednax Inc is regarded fourth in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 41,229. Mednax retains roughly 5,450 in number of employees claiming about 13% of equities under Health Care industry.

Mednax Profit Margins

The company has Net Profit Margin (PM) of (0.03) %, which may indicate that it does not properly execute on its own pricing strategies. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.08 %, which signifies that for every $100 of sales, it has a net operating income of $0.08.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.20.2113
Notably Down
Slightly volatile
Operating Profit Margin0.00350.0037
Notably Down
Slightly volatile

Mednax Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mednax insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mednax's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mednax insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2023-06-01
1.0
8
8
 86,084 
 73,126 
2023-03-01
0.7143
5
7
 246,200 
 26,589 
2022-06-01
6.0
6
1
 50,880 
 8,480 
2022-03-01
0.8889
8
9
 305,013 
 245,969 
2021-09-01
0.125
1
8
 95,000 
 728,291 
2021-06-01
3.3333
10
3
 48,850 
 107,858 
2021-03-01
2.0
10
5
 336,738 
 181,387 
2020-09-01
0.6923
9
13
 837,986 
 516,915 
2020-06-01
0.3333
1
3
 200,000 
 16,007 
2020-03-01
3.0
18
6
 472,834 
 82,822 
2019-09-01
3.0
6
2
 500,000 
 24,675 
2019-06-01
0.1667
1
6
 50,690 
 44,335 
2019-03-01
2.1111
19
9
 659,839 
 69,661 
2018-12-01
2.0
2
1
 69,000 
 0.00 
2018-06-01
0.5833
7
12
 108,668 
 166,479 
2018-03-01
6.6667
20
3
 356,288 
 18,927 
2017-12-01
2.0
6
3
 49,099 
 24,336 
2017-09-01
0.5
1
2
 3,000 
 6,000 
2017-06-01
3.6
18
5
 276,519 
 81,533 
2017-03-01
0.44
11
25
 80,860 
 255,615 
2016-12-01
1.1667
7
6
 80,396 
 78,296 
2016-09-01
0.1667
1
6
 1,500 
 3,000 
2016-06-01
1.5455
17
11
 240,269 
 182,989 
2016-03-01
0.5
2
4
 13,768 
 27,536 
2015-12-01
0.5
1
2
 5,250 
 10,500 
2015-09-01
0.5625
9
16
 114,120 
 268,950 
2015-06-01
2.4286
17
7
 234,979 
 193,721 
2015-03-01
0.3077
4
13
 54,336 
 231,220 
2014-12-01
0.52
13
25
 515,000 
 1,038,800 
2014-09-01
0.5
3
6
 123,580 
 241,127 
2014-06-01
1.4118
24
17
 521,847 
 620,271 
2014-03-01
0.5
9
18
 310,668 
 633,536 
2013-12-01
0.5714
8
14
 259,050 
 496,310 
2013-09-01
0.2857
4
14
 105,730 
 174,109 
2013-06-01
2.8333
17
6
 184,745 
 62,815 
2013-03-01
0.5
3
6
 88,048 
 176,096 
2012-12-01
0.3226
10
31
 96,251 
 300,583 
2012-09-01
0.3333
1
3
 8,792 
 18,746 
2012-06-01
4.0
16
4
 244,796 
 34,442 
2012-03-01
0.36
9
25
 75,653 
 320,900 
2011-09-01
1.0
4
4
 217,160 
 160,000 
2011-06-01
1.0
28
28
 321,141 
 309,567 
2011-03-01
0.6667
2
3
 10,931 
 18,931 
2010-12-01
0.4
2
5
 10,416 
 22,682 
2010-06-01
1.2941
22
17
 306,913 
 181,177 
2010-03-01
0.3333
2
6
 7,100 
 34,200 
2009-12-01
0.4468
21
47
 255,477 
 618,215 
2009-09-01
0.1364
3
22
 46,800 
 463,530 
2009-06-01
2.5714
18
7
 352,798 
 49,755 
2008-09-01
0.0571
2
35
 100,000 
 299,382 
2008-06-01
15.0
15
1
 420,672 
 0.00 
2008-03-01
0.8
8
10
 69,778 
 77,778 
2007-12-01
2.25
9
4
 45,259 
 153,787 
2007-09-01
0.3902
16
41
 449,016 
 602,368 
2007-03-01
0.3333
1
3
 10,000 
 30,000 
2006-06-01
0.4348
20
46
 386,692 
 164,906 
2006-03-01
0.1077
7
65
 175,832 
 351,004 
2005-12-01
0.3684
14
38
 202,799 
 570,465 
2005-09-01
0.4242
14
33
 255,983 
 331,266 
2005-06-01
0.1827
19
104
 254,667 
 552,584 
2005-03-01
0.25
3
12
 21,666 
 103,332 
2004-12-01
0.2
2
10
 20,000 
 100,000 
2004-09-01
0.3333
6
18
 70,000 
 200,000 
2004-06-01
0.8889
16
18
 358,250 
 174,000 
2004-03-01
0.6667
16
24
 193,801 
 321,635 
2003-12-01
0.5333
8
15
 64,033 
 130,080 

Mednax Notable Stakeholders

A Mednax stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mednax often face trade-offs trying to please all of them. Mednax's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mednax's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James MDCEO DirectorProfile
Roger MedelChief Executive Officer, DirectorProfile
Mark OrdanChief Executive Officer, DirectorProfile
Cesar AlvarezIndependent Chairman of the BoardProfile
Kevin SmithInterim Vice President - Advanced Practice AnesthesiaProfile
Michael StanleyPresident - Pediatrix DivisionProfile
Dominic AndreanoExecutive Vice President, General Counsel, SecretaryProfile
C RichardsChief Financial Officer, Executive Vice President, Principal Accounting OfficerProfile
Stephen FarberChief Financial Officer, Executive Vice PresidentProfile
John PepiaSenior Vice President, Chief Accounting OfficerProfile
Charles LynchVice President - Strategy and Investor Relations, IR Contact OfficerProfile
Karl WagnerPresident of American AnesthesiologyProfile
Vivian LopezBlancoCFO, TreasurerProfile
Marc RichardsExecutive CFOProfile
David ClarkCOO - Pediatrix Medical GroupProfile
William HawkCOO - American AnesthesiologyProfile
Joseph CalabroPres and COOProfile
Curtis MDExecutive COOProfile
Enrique SosaIndependent DirectorProfile
Paul GabosIndependent DirectorProfile
Pascal GoldschmidtIndependent DirectorProfile
Donna ShalalaIndependent DirectorProfile
Waldemar CarloIndependent DirectorProfile
Manuel KadreLead Independent DirectorProfile
Michael FernandezIndependent DirectorProfile
Karey BarkerIndependent DirectorProfile
Charles CFAStrategy FinanceProfile
Nikos NikolopoulosExecutive Vice President Chief Strategy and Growth OfficerProfile
Michael RuckerIndependent DirectorProfile
Mary MooreExecutive Vice President Chief Enterprise Risk and Legal Operations OfficerProfile
Carlos MigoyaIndependent DirectorProfile
John StarcherIndependent DirectorProfile
Shirley WeisIndependent DirectorProfile
Roger HinsonPresident Pediatrix and Obstetrix Medical GroupProfile
Meghan LublinChief VPProfile
Dana DreherRodwellVP OfficerProfile
Guy SansoneIndependent Chairman of the BoardProfile
Lee WoodExecutive OperationsProfile
Roger MDCoFounder DirectorProfile
Cheryl VanPattenSenior OfficerProfile
Thomas McEachinIndependent DirectorProfile
Cheryl VanPattanVP OfficerProfile
Daniel CorcoranSenior CareProfile

About Mednax Management Performance

The success or failure of an entity such as Mednax Inc often depends on how effective the management is. Mednax management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mednax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mednax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed 0  0 
Return On Assets(0.03)(0.03)
Return On Equity(0.07)(0.07)
The data published in Mednax's official financial statements usually reflect Mednax's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Mednax Inc. For example, before you start analyzing numbers published by Mednax accountants, it's critical to develop an understanding of what Mednax's liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Mednax's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mednax's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Mednax's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mednax Inc. Please utilize our Beneish M Score to check the likelihood of Mednax's management manipulating its earnings.

Mednax Workforce Analysis

Traditionally, organizations such as Mednax use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mednax within its industry.

Mednax Manpower Efficiency

Return on Mednax Manpower

Revenue Per Employee366K
Revenue Per Executive46.4M
Net Loss Per Employee11.1K
Net Loss Per Executive1.4M
Working Capital Per Employee17.3K
Working Capital Per Executive2.2M
When determining whether Mednax Inc is a strong investment it is important to analyze Mednax's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mednax's future performance. For an informed investment choice regarding Mednax Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mednax Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Mednax Inc information on this page should be used as a complementary analysis to other Mednax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Mednax Stock analysis

When running Mednax's price analysis, check to measure Mednax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mednax is operating at the current time. Most of Mednax's value examination focuses on studying past and present price action to predict the probability of Mednax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mednax's price. Additionally, you may evaluate how the addition of Mednax to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Is Mednax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mednax. If investors know Mednax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mednax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.31)
Revenue Per Share
24.265
Quarterly Revenue Growth
(0.03)
Return On Assets
0.0432
Return On Equity
(0.07)
The market value of Mednax Inc is measured differently than its book value, which is the value of Mednax that is recorded on the company's balance sheet. Investors also form their own opinion of Mednax's value that differs from its market value or its book value, called intrinsic value, which is Mednax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mednax's market value can be influenced by many factors that don't directly affect Mednax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mednax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mednax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mednax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.